Skip to content
StockMarketAgent
Direct answer
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Stock analysis

MCK MCK fair value $737–$1,308

MCK
By StockMarketAgent.AI team· supervised by
Analisado: 2026-05-13Próxima atualização: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Preço
$725.17
▲ +290.95 (+40.12%)
Valor justo
$1016
$737–$1308
Classificação
Compra forte
confidence 79/100
Potencial de alta
+40.1%
upside to fair value
Margem de segurança
$863.70
MoS level · 15%
Capitalização de mercado
$87.2B
P/E fwd 14.4
Fonte em inglêsPT
Exibindo a fonte em inglês enquanto traduzimos
Este relatório ainda não foi traduzido. Atualize em alguns minutos assim que a fila de tradução recuperar o atraso.

§1 Resumo executivo

  • Composite fair value $1,016 with high case $1,308.
  • Implied upside of 40.1% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92

MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Immense scale forming an entrenched
    Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
  • High barriers to entry due
    High barriers to entry due to extreme capital and regulatory requirements.
  • Cycle upside
    Aging demographics and expanded specialty drug approvals drive sustained volume growth.

§2 Cenário pessimista

A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.

Como esta tese pode falhar

Major Retail Network Loss

· Low

The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.

FV impact
-25%

Regulatory Margin Collapse

· Medium

Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.

FV impact
-30%

Resurgent Litigation

· Low

Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.

FV impact
-15%
Sinais de alerta antecipado para monitorar
MétricaAtualLimite de gatilho
Operating margins slipping below 1.2% for consecutive quarters.MonitorDeterioration versus the report thesis
Cancellation or significant reduction of the annual share repurchase program.MonitorDeterioration versus the report thesis
Loss of major customer contracts in the retail pharmacy segment.MonitorDeterioration versus the report thesis
Slowing revenue growth in the higher-margin specialty oncology segment.MonitorDeterioration versus the report thesis
Deteriorating free cash flow conversion ratios.MonitorDeterioration versus the report thesis

§3 Histórico financeiro

Demonstração de resultados — últimos seis períodos
ItemT−0T−1T−2T−3CAGR
Período2022-03-312023-03-312024-03-312025-03-31Trend
Receita$263.97B$276.71B$308.95B$359.05B+10.8%
Lucro bruto$13.13B$12.36B$12.83B$13.32B+0.5%
Lucro operacional$2.59B$4.58B$4.17B$4.82B+22.9%
Lucro líquido$1.11B$3.56B$3.00B$3.30B+43.5%
LPA (diluído)$7.23$25.03$22.39$25.72+52.7%
EBITDA$2.87B$5.49B$4.68B$5.26B+22.4%
P&D
SG&A$10.54B$7.78B$8.66B$8.51B-6.9%

Pontuações de qualidade

OCF / Lucro líquido
1.85×
>1 indica alta qualidade dos lucros
Limite de qualidade contábil
Fail
Limite ajustado ao setor
ROIC
68.7%
Retorno sobre o capital investido
Seção 3

Numbers analysis

Fluxo de caixa

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Alocação de capital

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Assinantes individuais — a partir do §411 seções a mais

Leia a análise completa — 11 seções a mais.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Relatório completo para cada ticker coberto
24 meses de arquivo de classificações
Briefings da lista de acompanhamento + alertas de mudança de classificação
Exportação PDF + DOCX em qualquer idioma
Iniciar teste grátis
Cancele a qualquer momento.
FAQ

MCK — frequently asked questions

  1. Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Related coverage

Names readers of MCK also follow

Same archetype: mature-compounder